A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia.

Trial Profile

A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Ofatumumab (Primary)
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 28 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Dec 2012 Planned End Date changed from 1 Mar 2013 to 1 Aug 2014 as reported by ClinicalTrials.gov.
    • 12 Aug 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top